BACKGROUND: Extra @entity706 (ENL) constitutes about 33 % of all @entity1893 . 18-28% develops in the head and neck region. A multimodality treatment with multi-agent chemotherapy (CT) and radiotherapy (RT) is considered optimum. MATERIALS AND METHODS: We retrieved the treatment charts of @entity1 of @entity135 treated in our institute from 2001-2012. The charts were reviewed and the demographic, treatment details and outcome of @entity135 @entity1 were retrieved using predesigned pro-forma. RESULTS: We retrieved data of 75consecutive @entity1 @entity135 . Median age was 47years (Range: 8-76 years). Of the 75 @entity1 51 were male and 24 were female. 55 @entity1 were evaluable. The @entity1 and @entity5 characteristics are summarized in Table 1. All @entity1 were staged comprehensively with contrast enhanced computed tomography of head, neck, thorax, abdomen, pelvis and @entity236 and biopsy 66 @entity1 received a combination multi-agent CT with @entity3726 being the commonest regimen. 42 @entity1 received 4 or lesser number of cycles of chemotherapy whereas 24received more than 4 cycles chemotherapy. Post radiotherapy, 41 out of 42 @entity1 had a complete response at 3 months. Only 21 @entity1 had a complete response after chemotherapy. All @entity1 received radiation (mostly involved field radiation) as a part of the treatment. The median radiation dose was 45 Gray (Range: 36 Gray-50 Gray). The radiation was planned by 2D fluoro simulation based technique in 37cases and by 3 Dimensional conformal radiation therapy (3DCRT) in 36 cases. Two @entity1 were planned by the intensity modulated radiation therapy (IMRT) technique. IMRT was planned for one thyroid and one nasal cavity primary. 5 @entity1 experienced relapse after a median follow up of 19 months. The median survival was not reached. The estimated two and three year survival were 92.9% (95%CI- 68.6- 95.35) and 88% (95%CI- 60.82 - 92.66) respectively. Univariate analysis revealed higher stage and poorer baseline performance status to be significantly associated with worse progression free survival. 5 @entity1 progressed (relapse or @entity66 progression) after treatment. Of the 5 @entity1 , two @entity1 were @entity2694 , two @entity1 had @entity1893 nasal cavity and one was @entity1893 thyroid. CONCLUSIONS: Combined modality treatment in @entity135 confers excellent disease control with acceptable side effects.

@entity135 ( XXXX ) - Treatment Outcome and Pattern of failure - A Single Institution Experience.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity135 :: ('MESH:D006258', 'Disease') :: ['HNENL'] @entity66 :: ('MESH:D004194', 'Disease') :: ['primary disease'] @entity706 :: ('MESH:D008223', 'Disease') :: ['nodal lymphoma'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity3726 :: ('1649', 'Gene') :: ['CHOP'] @entity2694 :: ('MESH:D009916', 'Disease') :: ['primary orbital NHL'] @entity1893 :: ('MESH:D008228', 'Disease') :: ["non-Hodgkin's lymphoma", 'NHL'] @entity236 :: ('MESH:D001855', 'Disease') :: ['bone marrow aspiration']
@entity135 :: (MESH:D006258,Disease) :: ['HNENL']
